This delayed emptying augments both the volume and acidity of gastric contents at induction, increasing the odds of pulmonary aspiration during intubation
For patients with type 2 diabetes and Hashimoto's, options include: Semaglutide (Ozempic) : Once-weekly injection with robust efficacy for glycemic control, weight loss, and cardiovascular risk reduction Semaglutide (Rybelsus) : Oral daily tablet requiring careful timing with levothyroxine Dulaglutide (Trulicity) : Once-weekly injection with established cardiovascular benefits Liraglutide (Victoza) : Daily injection with cardiovascular risk reduction and extensive long-term safety data Tirzepatide (Mounjaro) : Once-weekly injection combining GLP-1 and GIP receptor agonism, showing superior efficacy in clinical trials For patients with obesity and Hashimoto's, FDA-approved options include: Semaglutide (Wegovy) : Once-weekly injection at higher doses than Ozempic Liraglutide (Saxenda) : Daily injection Tirzepatide (Zepbound) : Once-weekly injection with significant weight loss efficacy The presence of Hashimoto's thyroiditis does not inherently favor one GLP-1 medication over another
As your appetite, hydration, and meal patterns change over time, this type of structure can help support better long-term consistency and daily balance
Wearing a supportive bra that does not dig in
Concerns over more severe adverse effects, including pancreatitis and possible thyroid tumors, may further deter both patients and healthcare providers from utilizing these medications
If you are navigating a medico-legal obstacle, visit our booking page to schedule a consultation or use the tool shared below
